

### **Apostle Inc Presents at the Precision Medicine World Conference 2020**

For immediate release

**MENLO PARK, CA, January 23, 2020** – Apostle Inc today presents at the Precision Medicine World Conference (PMWC) 2020 held in Santa Clara, California.

David Ge, CEO of Apostle Inc, attended the conference and presented in the conference’s Liquid Biopsy Showcase track. The PMWC 2020 Liquid Biopsy Showcase provides a 15-minute time slot for selected liquid biopsy companies to present their latest technologies to an audience of leading investors, potential clients, and partners. The track features companies that advance the development of screening tests for oncology, immunotherapy, and other areas, based on detection and identification of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), circulating RNA, circulating microRNAs, or extracellular vesicle (exosomes).

“cfDNA isolation, purification, and selection is a critical yet unaddressed challenge in liquid biopsy.” David said, “The acclaimed Apostle MiniMax high efficiency cfDNA isolation technology, as well as the new incoming Apostle MiniEnrich short-fragment cfDNA selection technology, answers for this challenge and ensures a successful liquid biopsy test.”

For more information about this presentation, visit:  
[https://www.pmwciintl.com/speaker/david-ge\\_apostle\\_2020sv/](https://www.pmwciintl.com/speaker/david-ge_apostle_2020sv/)

#### **About Apostle Inc**

Apostle Inc is a biotechnology company in Menlo Park, CA, aiming to develop innovative technologies in the space of liquid biopsy - the sampling and analysis of non-solid biological tissue, primarily blood, often utilizing circulating free DNA (cfDNA) as a biomarker. Apostle’s innovations include Apostle MiniMax™, a new scalable and automatable method to efficiently capture cfDNA from a standard blood draw. More information can be found at [www.apostlebio.com](http://www.apostlebio.com). Contact: [info@apostlebio.com](mailto:info@apostlebio.com)